Disclosed are compositions comprising docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), linoleic acid (LA), gamma linolenic add (GLA), and other omega-3 polyunsaturated fatty acids (PUFAs), monounsaturated fatty acids (MUFAs), and saturated fatty acids (SFAs). Also disclosed are compositions further comprising gamma tocopherol, Vitamin A, and Vitamin E. The compositions are useful for treating neurologic disorders. The compositions are administered chronically for the prevention and/or treatment of multiple sclerosis (MS) and other degenerative diseases.
